IgA Nephropathy- Pipeline Insight, 2021
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “IgA Nephropathy – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in IgA Nephropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
IgA Nephropathy: Overview
IgA nephropathy, also known as Berger’s disease, is a kidney disease that occurs when IgA deposits build up in the kidneys, causing inflammation that damages kidney tissues. IgA is an antibody—a protein made by the immune system to protect the body from foreign substances such as bacteria or viruses. It is not known what causes IgA deposits in the glomeruli. In more than 10% of affected families, it is inherited. Each person may have a different set of signs and symptoms from IgAN. The Most common symptoms are: Hematuria and Proteinuria, Swelling in ankles and High Blood pressure. Urine test, Blood test, Glomerular Filtration rate, Kidney Biopsy are some of the procedures that helps in the diagnosis of IgA Nephropathy. There is no cure for IgA nephropathy, but treatments can help to prevent more damage to your kidneys.
“IgA Nephropathy - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the IgA Nephropathy pipeline landscape is provided which includes the disease overview and IgA Nephropathy treatment guidelines. The assessment part of the report embraces, in depth IgA Nephropathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, IgA Nephropathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence IgA Nephropathy R&D. The therapies under development are focused on novel approaches to treat/improve IgA Nephropathy.
IgA Nephropathy Emerging Drugs Chapters
This segment of the IgA Nephropathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
IgA Nephropathy Emerging Drugs
Atrasentan: Chinook Therapeutics
Atrasentan is a potent and selective, small molecule inhibitor of the endothelin A receptor for the potential treatment of IgA Nephropathy (IgAN) and other proteinuric glomerular diseases. Chinook Therapeutics plans to initiate a phase 3 trial (ALIGN) of Atrasentan in early 2021 in patients with IgAN at high risk of kidney function decline.
IONIS-FB-LRx: Ionis Pharmaceuticals
IONIS-FB-LRx is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of complement factor B (FB). Ionis Pharmaceuticals is leading phase II trials for IONIS-FB-LRx.
Sparsentan: Travere Therapeutics
Sparsentan is an investigational product candidate currently being evaluated for the treatment of IgAN, as well as focal segmental glomerulosclerosis (FSGS) in pivotal Phase 3 clinical trials that are expected to report topline data from interim proteinuria assessments in 2021.
Further product details are provided in the report……..
IgA Nephropathy: Therapeutic Assessment
This segment of the report provides insights about the different IgA Nephropathy drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in IgA Nephropathy
There are approx. 10+ key companies which are developing the therapies for IgA Nephropathy. The companies which have their IgA Nephropathy drug candidates in the most advanced stage, i.e. phase III include, Chinook Therapeutics.
Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
IgA Nephropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
IgA Nephropathy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses IgA Nephropathy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging IgA Nephropathy drugs.
IgA Nephropathy Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “IgA Nephropathy – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in IgA Nephropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
IgA Nephropathy: Overview
IgA nephropathy, also known as Berger’s disease, is a kidney disease that occurs when IgA deposits build up in the kidneys, causing inflammation that damages kidney tissues. IgA is an antibody—a protein made by the immune system to protect the body from foreign substances such as bacteria or viruses. It is not known what causes IgA deposits in the glomeruli. In more than 10% of affected families, it is inherited. Each person may have a different set of signs and symptoms from IgAN. The Most common symptoms are: Hematuria and Proteinuria, Swelling in ankles and High Blood pressure. Urine test, Blood test, Glomerular Filtration rate, Kidney Biopsy are some of the procedures that helps in the diagnosis of IgA Nephropathy. There is no cure for IgA nephropathy, but treatments can help to prevent more damage to your kidneys.
“IgA Nephropathy - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the IgA Nephropathy pipeline landscape is provided which includes the disease overview and IgA Nephropathy treatment guidelines. The assessment part of the report embraces, in depth IgA Nephropathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, IgA Nephropathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence IgA Nephropathy R&D. The therapies under development are focused on novel approaches to treat/improve IgA Nephropathy.
IgA Nephropathy Emerging Drugs Chapters
This segment of the IgA Nephropathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
IgA Nephropathy Emerging Drugs
Atrasentan: Chinook Therapeutics
Atrasentan is a potent and selective, small molecule inhibitor of the endothelin A receptor for the potential treatment of IgA Nephropathy (IgAN) and other proteinuric glomerular diseases. Chinook Therapeutics plans to initiate a phase 3 trial (ALIGN) of Atrasentan in early 2021 in patients with IgAN at high risk of kidney function decline.
IONIS-FB-LRx: Ionis Pharmaceuticals
IONIS-FB-LRx is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of complement factor B (FB). Ionis Pharmaceuticals is leading phase II trials for IONIS-FB-LRx.
Sparsentan: Travere Therapeutics
Sparsentan is an investigational product candidate currently being evaluated for the treatment of IgAN, as well as focal segmental glomerulosclerosis (FSGS) in pivotal Phase 3 clinical trials that are expected to report topline data from interim proteinuria assessments in 2021.
Further product details are provided in the report……..
IgA Nephropathy: Therapeutic Assessment
This segment of the report provides insights about the different IgA Nephropathy drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in IgA Nephropathy
There are approx. 10+ key companies which are developing the therapies for IgA Nephropathy. The companies which have their IgA Nephropathy drug candidates in the most advanced stage, i.e. phase III include, Chinook Therapeutics.
Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
IgA Nephropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
IgA Nephropathy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses IgA Nephropathy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging IgA Nephropathy drugs.
IgA Nephropathy Report Insights
- IgA Nephropathy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing IgA Nephropathy drugs?
- How many IgA Nephropathy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of IgA Nephropathy?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the IgA Nephropathy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for IgA Nephropathy and their status?
- What are the key designations that have been granted to the emerging drugs?
- Novartis AG
- Reata Pharmaceuticals
- Chinook Therapeutics
- Aravive, Inc.
- Omeros Corporation
- Travere Therapeutics
- Calliditas Therapeutics
- Vera Therapeutics, Inc.
- Apellis Pharmaceuticals, Inc.
- Atrasentan
- LNP023
- Nefecon
- Sparsentan
- BION-301
- AVB-500
- IONIS-FB-LRx
- APL-2
Introduction
Executive Summary
IgA Nephropathy: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
IgA Nephropathy – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
IgA Nephropathy companies’ collaborations, Licensing, Acquisition -Deal Value Trends
IgA Nephropathy Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Atrasentan: Chinook Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
IONIS-FB-LRx: Ionis Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
BION-1301: Chinook Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
IgA Nephropathy Key Companies
IgA Nephropathy Key Products
IgA Nephropathy- Unmet Needs
IgA Nephropathy- Market Drivers and Barriers
IgA Nephropathy- Future Perspectives and Conclusion
IgA Nephropathy Analyst Views
IgA Nephropathy Key Companies
Appendix
Executive Summary
IgA Nephropathy: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
IgA Nephropathy – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
IgA Nephropathy companies’ collaborations, Licensing, Acquisition -Deal Value Trends
IgA Nephropathy Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Atrasentan: Chinook Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
IONIS-FB-LRx: Ionis Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
BION-1301: Chinook Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
IgA Nephropathy Key Companies
IgA Nephropathy Key Products
IgA Nephropathy- Unmet Needs
IgA Nephropathy- Market Drivers and Barriers
IgA Nephropathy- Future Perspectives and Conclusion
IgA Nephropathy Analyst Views
IgA Nephropathy Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for IgA Nephropathy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for IgA Nephropathy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for IgA Nephropathy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for IgA Nephropathy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
